Western Sydney University’s National Institute of Complementary Medicine (NICM) is a leader in integrative and complementary medicine research and policy in Australia. NICM plays a key national role in ensuring Australians have access to reliable evidence on complementary medicines and treatments in wide use. As an ERA 5 ranking institute, NICM is globally recognised for its world-class research and innovations in integrative and complementary medicine. NICM’s research includes clinical trials, laboratory testing and policy work.
The Max Biocare Institute has partnered with NICM to trial the effectiveness of Hominax for improving sperm health in Australian men. To find out more information, please visit the Research and Innovation Platform at the MBCI or NICM.
Max Biocare & NICM
Trial topic
Sperm health
Trial center
National Institute of complementary Medicine (NICM) hosted by Western Sydney University in Australia.
Objective
To assess the effect of Hominax—a TGA listed product consisting of 15 active ingredients, including antioxidants, herbs, nutrients and vitamins—on the sperm health of men.
Sample
Healthy men aged between 20-60 years old, with mild to moderate infertility.
Methods
Clinical intervention will follow an open-label, single arm design. Males will receive 2 capsules of Hominax each day for 24 weeks. The primary outcome measures include changes in sperm concentration, motility and morphology. Secondary outcome measures include the number of confirmed pregnancy as well as changes in lipid peroxidation of seminal plasma and sperm, sperm DNA fragmentation by semen sample, semen volume, semen pH and homocysteine levels by blood sample. In addition, we will also assess changes in serum micronutrient status of B12, zinc and folate. Adverse events will be monitored by an Adverse Events Log. This study is registered with the Australian New Zealand Clinical Trials Register.
Results
This trial is currently recruiting participants. To participate in this trial, please visit our information page.
Contact Details
Or
